FFO
ALLO icon

Fortitude Family Office’s Allogene Therapeutics ALLO Stock Holding History

Fortitude Family Office’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Buy
1,229
+185
+18% +$371 ﹤0.01% 1127
2025
Q4 		$1.43K Buy
+1,044
New +$1.38K ﹤0.01% 1313
2025
Q3 		– Sell
-747
Closed -$844 – 1982
2025
Q2 		$844 Buy
+747
New +$993 ﹤0.01% 1589

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fortitude Family Office's ALLO Position: Q1 2026 in Review

Fortitude Family Office increased its Allogene Therapeutics (ALLO) stake by 18% in Q1 2026, buying an estimated $371 and bringing the position to 1,229 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1127.

Fortitude Family Office first reported a position in ALLO in Q2 2025 and has held it in 3 quarters since. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Fortitude Family Office held 1,229 shares of Allogene Therapeutics worth $3K as of Q1 2026.
  • Fortitude Family Office bought 185 Allogene Therapeutics shares in Q1 2026, an estimated $371.
  • Allogene Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1127 holding.
  • Fortitude Family Office first reported a position in Allogene Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.